Confocal immunofluorescent analysis of HeLa cells using PP2A A Subunit (81G5) Rabbit mAb (green). Actin filaments have been labeled with Alexa Fluor® 555 phalloidin (red).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using PP2A B Subunit (100C1) Rabbit mAb.
Flow cytometric analysis of HeLa cells, using PP2A C Subunit (52F8D8) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using PP2A A Subunit (81G5) Rabbit mAb.
Western blot analysis of cell lysates from HeLa, NIH/3T3, C6 and COS cells, using PP2A B Subunit (100C1) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using PP2A C Subunit (52F8D8) Rabbit mAb in the presence of an irrelevant control peptide (left) or PP2A C Subunit Blocking Peptide #1067 (right).
Western blot analysis of extracts from various cell lines using PP2A A Subunit (81G5) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using PP2A C Subunit (52F8D8) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human prostate carcinoma, using PP2A C Subunit (52F8D8) Rabbit mAb.
Western blot analysis of extracts from HeLa, NIH/3T3, C6 and COS cells, using PP2A C (52F8D8) Rabbit mAb.
|PP2A A Subunit (81G5) Rabbit mAb 2041||20 µl||
||H Mk M R||62||Rabbit IgG|
|PP2A B Subunit (100C1) Rabbit mAb 2290||20 µl||
||Dm H Mk M R||52||Rabbit IgG|
|PP2A C Subunit (52F8) Rabbit mAb 2259||20 µl||
||Dm H Mk M R||36, 38||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody 7074||100 µl||
The PP2A Antibody Sampler Kit provides an economical means of evaluating PP2A protein. The kit contains enough primary and secondary antibodies to perform two western blots with each antibody.
PP2A A Subunit (81G5) Rabbit mAb detects endogenous levels of α and β isoforms of the PP2A A subunit and does not cross-react with other PP2A subunits. PP2A B Subunit (100C1) Rabbit mAb detects endogenous levels of the α isoform of PP2A B and may recognize the β, γ, and δ isoforms of PP2A B. The antibody does not cross-react with the B', B'' or B''' families of PP2A B subunits. PP2A C Subunit (52F8) Rabbit mAb detects endogenous levels of α and β isoforms of the PP2A catalytic subunit and does not cross-react with other PP2A subunits.
Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to the sequence of human PP2A A, B, or C subunit proteins.
Protein phosphatase type 2A (PP2A) is an essential protein serine/threonine phosphatase that is conserved in all eukaryotes. PP2A is a key enzyme within various signal transduction pathways as it regulates fundamental cellular activities such as DNA replication, transcription, translation, metabolism, cell cycle progression, cell division, apoptosis and development (1-3). The core enzyme consists of catalytic C and regulatory A (or PR65) subunits, with each subunit represented by α and β isoforms (1). Additional regulatory subunits belong to four different families of unrelated proteins. Both the B (or PR55) and B' regulatory protein families contain α, β, γ and δ isoforms, with the B' family also including an ε protein. B'' family proteins include PR72, PR130, PR59 and PR48 isoforms, while striatin (PR110) and SG2NA (PR93) are both members of the B''' regulatory protein family. These B subunits competitively bind to a shared binding site on the core A subunit (1). This variable array of holoenzyme components, particularly regulatory B subunits, allows PP2A to act in a diverse set of functions. PP2A function is regulated by expression, localization, holoenzyme composition and post-translational modification. Phosphorylation of PP2A at Tyr307 by Src occurs in response to EGF or insulin and results in a substantial reduction of PP2A activity (4). Reversible methylation on the carboxyl group of Leu309 of PP2A has been observed (5,6). Methylation alters the conformation of PP2A, as well as its localization and association with B regulatory subunits (6-8).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.